Drug Interactions between Crixivan and etravirine
This report displays the potential drug interactions for the following 2 drugs:
- Crixivan (indinavir)
- etravirine
Interactions between your drugs
indinavir etravirine
Applies to: Crixivan (indinavir) and etravirine
GENERALLY AVOID: Coadministration of etravirine and protease inhibitors without concomitant ritonavir as a pharmacokinetic booster may produce significant alterations in plasma concentrations of the protease inhibitor. Etravirine is an inducer of CYP450 3A4 and inhibitor of CYP450 2C19 and 2C9, thus it may variously affect the metabolism and clearance of protease inhibitors. In unboosted pharmacokinetic regimens, etravirine has reduced plasma levels of atazanavir and indinavir and increased levels of amprenavir and nelfinavir. However, significant interactions affecting either etravirine and/or protease inhibitor plasma concentrations have also been observed with boosted regimens, including atazanavir/ritonavir, fosamprenavir/ritonavir, and tipranavir/ritonavir.
MANAGEMENT: Protease inhibitors should not be prescribed with etravirine in the absence of low-dose ritonavir as a pharmacokinetic booster.
References (1)
- (2008) "Product Information. Intelence (etravirine)." Ortho Biotech Inc
Drug and food interactions
indinavir food
Applies to: Crixivan (indinavir)
ADJUST DOSING INTERVAL: According to the manufacturer, coadministration with a meal high in calories, fat, and protein reduces the absorption of indinavir. In ten patients given indinavir in this manner, the peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) of indinavir decreased by an average of 84% and 77%, respectively. In contrast, grapefruit juice may have only minor effects on the oral bioavailability of indinavir. The manufacturer's package labeling states that administration of a single 400 mg dose of indinavir with 8 oz. of grapefruit juice decreased indinavir AUC by an average of 26%. Likewise, a study consisting of 14 HIV-infected subjects found no uniform nor significant changes in steady-state indinavir AUC during administration with double-strength grapefruit juice compared to water. There was, however, a delay in absorption (Tmax) due to grapefruit juice that is unlikely to be of clinical significance.
MANAGEMENT: To ensure maximal oral absorption, indinavir should be administered without food but with water 1 hour before or 2 hours after a meal. Alternatively, indinavir may be administered with other liquids such as skim milk, juice, coffee, or tea, or with a light meal (e.g., dry toast with jelly, juice, and coffee with skim milk and sugar; corn flakes, skim milk and sugar).
References (3)
- (2001) "Product Information. Crixivan (indinavir)." Merck & Co., Inc
- Yeh KC, Deutsch PJ, Haddix H, Hesney M, Hoagland V, Ju WD, Justice SJ, Osborne B, Sterrett AT, Stone JA, Woolf E, Waldman S (1998) "Single-dose pharmacokinetics of indinavir and the effect of food." Antimicrob Agents Chemother, 42, p. 332-8
- Shelton MJ, Wynn HE, Newitt RG, DiFrancesco R (2001) "Effects of grapefruit juice on pharmacokinetic exposure to indinavir in HIV-positive subjects." J Clin Pharmacol, 41, p. 435-42
etravirine food
Applies to: etravirine
ADJUST DOSING INTERVAL: Coadministration with food increases the oral bioavailability of etravirine. The mechanism is unknown. Compared to administration following a meal, the systemic exposure (AUC) to etravirine was decreased by about 50% when the drug was administered under fasting conditions. The types of meal studied (ranging from 345 kilocalories containing 17 grams fat to 1160 kilocalories containing 70 grams fat) did not appear to make a difference with respect to impact on etravirine bioavailability.
MANAGEMENT: Etravirine should always be administered following a meal.
References (1)
- (2008) "Product Information. Intelence (etravirine)." Ortho Biotech Inc
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.